Lonapegsomatropin-tcgd
Brand names: Skytrofa · Active ingredient: Lonapegsomatropin
In short: SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the: Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH). Replacement of endogenous growth hormone in adults with gr
What is Lonapegsomatropin-tcgd used for?
SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the:
Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).
Replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
Lonapegsomatropin-tcgd dosage
For subcutaneous injection, once weekly.
Therapy with SKYTROFA should be supervised by a healthcare provider who is experienced in the diagnosis and management of patients with growth hormone deficiency (GHD).
Perform fundoscopic examination before initiating treatment with SKYTROFA to exclude preexisting papilledema. If papilledema is identified, evaluate the etiology and treat the underlying cause before initiating treatment with SKYTROFA .
The recommended dose of SKYTROFA for treatment-naïve patients and patients switching from another growth hormone product is 0.24 mg/kg body weight, given once weekly.
Individualize and titrate the dosage of SKYTROFA based on response.
When changing from daily somatropin therapy to once-weekly SKYTROFA, wait at least 8 hours between the final dose of daily somatropin and the first dose of SKYTROFA.
When changing from another once-weekly growth hormone therapy to once-weekly SKYTROFA, wait at least 7 days between the final dose of the previous growth hormone therapy and the first dose of SKYTROFA.
Assess compliance and evaluate other causes of poor growth, such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human growth hormone if patients experience failure to increase height velocity, particularly during the first year of treatment.
Patients who were treated with SKYTROFA for GH deficiency in childhood and whose epiphyses are closed should be reevaluated before continuing SKYTROFA.
The recommended starting dose of SKYTROFA in adults with GHD is based on age and concomitant use of oral estrogen . For treatment-naïve patients or for patients switching from another growth hormone product, start SKYTROFA as described below:
1.4 mg once weekly for adults 30 to 60 years old, with no oral estrogen intake
2.1 mg once weekly for adults under 30 years old, or adults of any age intaking oral estrogen
0.7 mg once weekly for adults over 60 years old, with no oral estrogen intake
When changing from daily somatropin therapy to once-weekly SKYTROFA, wait at least 8 hours between the final dose of daily somatropin and the first dose of SKYTROFA.
When changing from another once-weekly growth hormone therapy to once-weekly SKYTROFA, wait at least 7 days between the final dose of the previous growth hormone therapy and the first dose of SKYTROFA.
Increase the dose monthly to a higher strength cartridge based on the clinical response and/or IGF-1 concentration. Draw IGF-1 serum sample 4 to 5 days after the prior dose.
Decrease the dose to a lower strength cartridge as needed based on adverse reactions or a weekly average IGF-1 concentration above the age- and sex-specific normal range.
The maximum recommended dose is 6.3 mg once weekly. …
How to take Lonapegsomatropin-tcgd — instructions & advice from the label
Administration Instructions
Advise patients and/or caregivers to read the accompanying FDA-approved patient labeling SKYTROFA Auto-Injector Instructions for Use (also available at www.Skytrofa.com/IFU) prior to administration. Advise patients and/or caregivers to call the Ascendis Pharma Customer Support toll-free number at 1-844-442-7236 (1-844-44ASCENDIS) for assistance or additional training, if needed.
Advise patients and/or caregivers to refer to the Instructions for Use that accompanies the SKYTROFA Auto-Injector for complete mixing and administration instructions with illustrations . Instruct patients and/or caregivers of proper needle disposal and caution against any reuse of needles. An appropriate container for the disposal of used cartridge and needle should be used.
Advise patients and/or caregivers to administer SKYTROFA once weekly, at any time of day. Advise patients and/or caregivers that doses can be taken 2 days before or 2 days after the scheduled dosing day. Advise patients and/or caregivers to resume once-weekly dosing for the next dose. …
Warnings & precautions
Do not take this medicine if: SKYTROFA is contraindicated in patients with:
Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin .
Hypersensitivity to somatropin or any of the excipients in SKYTROFA. Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported .
Pediatric patients with closed epiphyses.
Active malignancy due to the risk of malignancy progression .
Active proliferative or severe non-proliferative diabetic retinopathy because treatment with somatropin may worsen this condition.
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to the risk of sudden death .
Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic doses of somatropin .
The safety of continuing SKYTROFA treatment in patients receiving replacement doses for the approved indication who concurrently develop these illnesses has not been established.
Severe systemic hypersensitivity reactions, including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products, including SKYTROFA. Inform patients and/or caregivers that such reactions are possible, and that prompt medical attention should be sought if an allergic reaction occurs. SKYTROFA is contraindicated in patients with known hypersensitivity to somatropin or any of the excipients in SKYTROFA. …
Lonapegsomatropin-tcgd side effects
The following important adverse reactions are described elsewhere in the labeling:
Increased mortality in patients with acute critical illness
Severe hypersensitivity
Increased risk of neoplasms
Glucose intolerance and diabetes mellitus
Intracranial hypertension
Fluid retention
Hypoadrenalism
Hypothyroidism
Slipped capital femoral epiphysis in pediatric patients
Progression of preexisting scoliosis in pediatric patients
Pancreatitis
Lipoatrophy
Sudden death in pediatric patients with Prader-Willi syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Pediatric Patients with Growth Hormone Deficiency
SKYTROFA was studied in a 52-week, open-label, active-controlled trial in 161 treatment-naïve, prepubertal pediatric patients with growth hormone deficiency (GHD) . The subjects ranged in age from 3.2 to 13.1 years with a mean of 8.5 years. One hundred thirty-two (82%) of the subjects were male and 29 (18%) were female. One subject was Asian, 3 were Black or African American, 152 were Caucasian, and 5 were categorized as "other."
Table 2 shows common adverse reactions that occurred in ≥ 5% of patients treated with SKYTROFA in this trial. …
Drug interactions
Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them.
Replacement Glucocorticoid Treatment
Clinical Impact: | Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11βHSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11βHSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.
Intervention: | Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA
Examples | Cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1. …
About this medicine
Lonapegsomatropin-tcgd is a long-acting prodrug of a human growth hormone (somatropin) produced by recombinant DNA technology using E. coli. Lonapegsomatropin-tcgd consists of a parent drug, somatropin, that is conjugated to a methoxypolyethylene glycol carrier (4 × 10 kDa mPEG) via a proprietary TransCon Linker and has a molecular weight of 63 kDa (released somatropin is 22 kDa). In vitro assay confirms the minimum potency of released somatropin is NLT 2.5 IU/mg.
SKYTROFA (lonapegsomatropin-tcgd) for injection is a sterile, preservative-free, white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and the diluent, Water for Injection, in the other chamber. SKYTROFA prefilled cartridge must be used with SKYTROFA Auto-Injector to provide an automatic mixing step for reconstitution prior to subcutaneous use. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9229f871-bc61-4ddc-8122-d126d40e36ac. Read the full official label on DailyMed.